| Christopher J Hussussian, MD | |
|
N74 W22370 Bluemound Rd, Waukesha, WI 53186 | |
| (262) 970-5600 | |
| (262) 970-5950 |
| Full Name | Christopher J Hussussian |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 34 Years |
| Location | N74 W22370 Bluemound Rd, Waukesha, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558329441 | NPI | - | NPPES |
| 34515700 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 46664-020 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Waukesha Memorial Hospital | Waukesha, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cj Hussussian Md Sc | 1456339993 | 4 |
News Archive
A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.
"A global push to bring a vaccine against the bacterial cause of pneumonia to communities that need it most is ramping up quickly, expanding to nearly 60 countries in the next five years," PBS NewsHour's "The Rundown" reports.
The introduction of screening colonoscopy in Germany is showing results: Within ten years of the start of this screening program for the early detection of colorectal cancer, the number of new cases has significantly dropped in the age groups 55 years and over.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
› Verified 7 days ago
| Entity Name | Cj Hussussian Md Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831260405 PECOS PAC ID: 1456339993 Enrollment ID: O20040710000316 |
News Archive
A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.
"A global push to bring a vaccine against the bacterial cause of pneumonia to communities that need it most is ramping up quickly, expanding to nearly 60 countries in the next five years," PBS NewsHour's "The Rundown" reports.
The introduction of screening colonoscopy in Germany is showing results: Within ten years of the start of this screening program for the early detection of colorectal cancer, the number of new cases has significantly dropped in the age groups 55 years and over.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher J Hussussian, MD N74 W22370 Bluemound Rd, Waukesha, WI 53186 Ph: (262) 970-5600 | Christopher J Hussussian, MD N74 W22370 Bluemound Rd, Waukesha, WI 53186 Ph: (262) 970-5600 |
News Archive
A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.
"A global push to bring a vaccine against the bacterial cause of pneumonia to communities that need it most is ramping up quickly, expanding to nearly 60 countries in the next five years," PBS NewsHour's "The Rundown" reports.
The introduction of screening colonoscopy in Germany is showing results: Within ten years of the start of this screening program for the early detection of colorectal cancer, the number of new cases has significantly dropped in the age groups 55 years and over.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
› Verified 7 days ago
Dr. Tracy E Mccall, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: N19w24075 Riverwood Dr Ste 228, Waukesha, WI 53188 Phone: 262-523-1200 Fax: 262-523-1230 | |
Thomas G Korkos, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: N4w22370 Bluemound Rd, 100, Waukesha, WI 53186 Phone: 262-970-5600 Fax: 262-970-5950 | |
Alex Colque, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 21675 E. Moreland Blvd., Suite 100, Waukesha, WI 53186 Phone: 262-781-9000 Fax: 262-395-4068 | |
Jenna Cusic, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: N4w22370 Bluemound Rd, Waukesha, WI 53186 Phone: 262-970-5605 |